Patent EA-005234-B1 (EA)
Title: Vaccine for immunization of vertebrates from brucellosis, vaccine for prophylaxis or treatment of vertebrates from brucellosis and method of producing the same, attenuated or avirulent version of b.abortis strain rb51, method for prophylaxis or treatment of vertebrates from brucellosis
Inventor: BOYLE STEPHEN M
IPC: A61K39/106
Filed: 1997-12-05
Abstract: 1. A vaccine for the immunization of vertebrates against Brucellosis, wherein said vaccine comprises an attenuated or avirulent pathogen of Brucella that over-expresses at least one homologous antigens encoded by at least one gene from said Brucella and wherein said at least one antigen is capable of inducing a protective immune response against the Brucellosis. 2. The vaccine of claim 1, wherein said attenuated or avirulent pathogen of Brucella further expresses one or more heterologous antigens. 3. A vaccine for prophylaxis or treatment of a vertebrate against Brucellosis, wherein said vaccine comprises an attenuated or avirulent pathogen of Brucella, wherein the attenuated or avirulent pathogen over-expresses at least one homologous antigen encoded by at least one gene from said pathogen, and wherein the at least one antigen is capable of inducing a protective immune response in the vertebrate against Brucellosis. 4. The vaccine of claim 3, wherein the pathogen is selected from the group consisting of B. aborts, B. melitensis, B. suis, and B. canis. 5. The vaccine of claim 4, wherein Brucella is B. abortus strain RB51 or a derivative thereof. 6. The vaccine of claim 5, wherein the at least one gene, encoding homologous antigen, is a Cu/Zn SOD gene. 7. The vaccine of claim 6, wherein the Cu/Zn gene is obtained from apUC19 genomic library of B. abortus strain 2308. 8. The vaccine of claim 6, wherein the at least one gene, encoding homologous antigen, is one or both of a GroES gene and a GroEL gene. 9. The vaccine of claim 8, wherein the GroES gene and the GroEL gene are obtained from apUC19 genomic library of B. abortus strain 2308. 10. The vaccine of claim 3, wherein the vertebrate is bovine. 11. An attenuated or avirulent version of B. abortus strain RB51 that over-expresses at least one homologous antigen capable of stimulating protective immunity against Brucellosis. 12. The attenuated or avirulent version of B. abortus strain RB51 of claim 11, wherein the at least one homologous antigen is encoded by at least one gene selected from the group consisting of a Cu/Zn SOD gene, a GroES gene and a GroEL gene. 13. A method for prophylaxis or treatment of a vertebrate from Brucellosis comprising administering an effective amount of vaccine of any one of claims 1-10. 14. The method of claim 13, wherein the vertebrate is human. 15. The method of claim 13, wherein said vaccine comprises pathogen of Brucella which further expresses one or more heterologous antigens. 16. The method of claim 13, wherein the at least one gene, encoding homologous antigen, is a Cu/Zn SOD gene. 17. The method of claim 16, wherein the Cu/Zn gene is obtained from apUC19 genomic library of B. abortus strain 2308. 18. The method of claim 13, wherein said vaccine comprises pathogen of Brucella in which at least one gene, encoding homologous antigen, is one or both of a GroES gene and a GroEL gene in B. abortus strain RB51. 19. The method of claim 18, wherein the GroES gene and the GroEL gene are obtained from apUC19 genomic library of B. abortus strain 2308. 20. A method of producing a vaccine strain for prophylaxis or treatment of a vertebrate from Brucellosis, comprising extracting deoxyribonucleic acid from pathogen of Brucella, identifying at least one gene encoding at least one homologous antigen, wherein said at least one antigen is capable of stimulating protective immunity against Brucellosis, inserting the at least one gene into a multicopy plasmid capable of replicating and expressing in the pathogenic Brucella micro-organism transforming an attenuated or avirulent version of the pathogenic Brucella micro-organism with the plasmid to form a strain, which is apart of vaccine of any one of claims 1-10. 21. The method of claim 20, wherein said attenuated or avirulent pathogen Brucella micro-organism further expresses one or more heterologous antigens. 22. The method of claim 20, wherein said strain is selected from the group consisting of B. aborts, B. melitensis, B. suis, B. ovis, B.neotomae and B. canis. 23. The method of claim 22, wherein said strain is B. abortus strain RB51. 24. The method of claim 23, wherein the at least one gene, encoding homologous antigen, is a Cu/Zn SOD gene. 25. The method of claim 23, wherein the at least one gene, encoding homologous antigen is one or both of a GroES gene and a GroEL gene.